Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

被引:2
|
作者
Fujisawa, Takuo [1 ]
Tsuta, Koji [2 ]
Yanagimoto, Hiroaki [3 ]
Yagi, Masao [1 ]
Suzuki, Kensuke [1 ]
Nishikawa, Kenji [4 ]
Takahashi, Masaru [4 ]
Okada, Hisatake [4 ]
Nakano, Yasushi [4 ]
Iwai, Hiroshi [1 ]
机构
[1] Kansai Med Univ, Dept Otolaryngol Head & Neck Surg, Osaka 5731010, Japan
[2] Kansai Med Univ, Dept Pathol & Lab Med, Osaka 5731010, Japan
[3] Kansai Med Univ, Dept Surg, Osaka 5731010, Japan
[4] Kon Minolta Inc, Corp R&D Headquarters, Bio Adv Technol Div, Bio Syst Dev Grp, Tokyo 1918511, Japan
关键词
programmed death ligand-1; digital immunostaining; ELISA; nCounter; EXPRESSION; PEMBROLIZUMAB;
D O I
10.3892/mco.2019.1801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 50 条
  • [1] Whole Slide Digital Imaging and Analysis of a PD-L1 Immunohistochemical Assay Is Quantifiably Reproducible
    Cohen, Jarish
    Bowman, Sarah
    Roberts, Daniel E.
    Walavalkar, Vighnesh
    Laszik, Laura
    Laszik, Zoltan
    LABORATORY INVESTIGATION, 2016, 96 : 511A - 511A
  • [2] Whole Slide Digital Imaging and Analysis of a PD-L1 Immunohistochemical Assay Is Quantifiably Reproducible
    Cohen, Jarish
    Bowman, Sarah
    Roberts, Daniel E.
    Walavalkar, Vighnesh
    Laszik, Laura
    Laszik, Zoltan
    MODERN PATHOLOGY, 2016, 29 : 511A - 511A
  • [3] PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
    Sunshine, Joel C.
    Nguyen, Peter L.
    Kaunitz, Genevieve J.
    Cottrell, Tricia R.
    Berry, Sneha
    Esandrio, Jessica
    Xu, Haiying
    Ogurtsova, Aleksandra
    Bleich, Karen B.
    Cornish, Toby C.
    Lipson, Evan J.
    Anders, Robert A.
    Taube, Janis M.
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4938 - 4944
  • [4] PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays
    Grabenstetter, Anne
    Jungbluth, Achim A.
    Frosina, Denise
    Hoda, Raza
    Dos Anjos, Carlos H.
    Patil, Sujata
    Sevilimedu, Varadan
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark E.
    Brogi, Edi
    Wen, Hannah Y.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (09) : 1274 - 1281
  • [5] Digital quantitative assessment of PD-L1 using digital spatial profiling
    Gupta, Swati
    Zugazagoitia, Jon
    Martinez-Morilla, Sandra
    Fuhrman, Kit
    Rimm, David L.
    LABORATORY INVESTIGATION, 2020, 100 (10) : 1311 - 1317
  • [6] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
    Grabenstetter, Anne
    Jungbluth, Achim
    Frosina, Denise
    Hoda, Raza
    Weigelt, Britta
    Reis-Filho, Jorge
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark
    Brogi, Edi
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 159 - 160
  • [7] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
    Grabenstetter, Anne
    Jungbluth, Achim
    Frosina, Denise
    Hoda, Raza
    Weigelt, Britta
    Reis-Filho, Jorge
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark
    Brogi, Edi
    Wen, Hannah
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 159 - 160
  • [8] PD-L1 immunostaining: what pathologists need to know
    Akhtar, Mohammed
    Rashid, Sameera
    Al-Bozom, Issam A.
    DIAGNOSTIC PATHOLOGY, 2021, 16 (01)
  • [9] An immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial cancer patients
    Zajac, M.
    Boothman, A. M.
    Nielsen, A.
    Manriques, G.
    Barker, C.
    Wang, P.
    Patil, P.
    Schechter, N.
    Rebelatto, M.
    Walker, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] PD-1 and PD-L1 antibodies for melanoma
    Tsai, Katy K.
    Zarzoso, Ines
    Daud, Adil I.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116